NewsSOS
A $2 million termination fee is now owed to Lisata Therapeutics, Inc.
failed to close a $4.00-per-share tender offer for the biotech, the company disclosed in a Form 8-K filed with the Securities and Exchange Commission Thursday.
Kuva Labs told Lisata it could not obtain sufficient financing, letting the offer expire without payment on July 20, 2026.
How the deal collapsed The merger agreement, dated March 6, 2026, called for Kuva Acquisition Corp., a wholly owned subsidiary of Kuva Labs, to acquire all outstanding shares of Lisata Therapeutics common stock through a tender offer at $4.00 per share in cash.
Keep reading